Dashboard
Manage Tickers

GRI GRI Bio, Inc.

Nasdaq gribio.com


$ 1.87 $ -0.04 (-2.05 %)    

Friday, 17-Oct-2025 11:46:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.25 $ 4.65 (0.78 %)
DIA $ 461.87 $ 2.50 (0.54 %)
SPY $ 662.93 $ 3.46 (0.52 %)
TLT $ 91.07 $ -0.16 (-0.18 %)
GLD $ 389.30 $ -7.88 (-1.99 %)
$ 1.95
$ 1.94
$ 1.86 x 9,900
$ 1.97 x 1,059
$ 1.87 - $ 1.94
$ 1.10 - $ 30.43
137,169
na
4.9M
$ 0.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-14-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 02-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 07-28-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-14-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
09/22/2025 12:09:30

ascendiant-capital-maintains-buy-on-gri-bio-raises-price-target-to-35
Ascendiant Capital Maintains Buy on GRI Bi...
09/22/2025 09:50:10

Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and raises the price target from $34 to $35.

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
09/12/2025 12:09:50

why-adobe-shares-are-trading-higher-by-over-4-here-are-20-stocks-moving-premarket
Why Adobe Shares Are Trading Higher By Ove...
09/12/2025 09:19:19

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/11/2025 21:06:02

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/11/2025 17:06:18

gri-bio-reports-interim-6-week-lung-function-results-from-ongoing-phase-2a-study-evaluating-gri-0621-for-treatment-of-idiopathic-pulmonary-fibrosis-phase-2a-study-fully-enrolled-topline-data-on-track-for-q3-2025
GRI Bio Reports Interim 6-Week Lung Functi...
09/11/2025 12:47:29

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker dataPhase 2a study fu...

gri-bio-q2-eps-131-inline
GRI Bio Q2 EPS $(1.31), Inline
08/14/2025 14:00:52

GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.31) per share which met the analyst consensus estimate. This is a 97.88 p...

crude-oil-falls-1-meta-earnings-top-views
Crude Oil Falls 1%; Meta Earnings Top Views
07/31/2025 17:25:08

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/31/2025 17:08:07

nasdaq-surges-over-1-microsoft-posts-upbeat-earnings
Nasdaq Surges Over 1%; Microsoft Posts Upb...
07/31/2025 14:12:21

gri-bio-reports-6-week-interim-biomarker-results-from-phase-2a-idiopathic-pulmonary-fibrosis-study-showing-favorable-reduction-in-fibrogenesis-biomarkers
GRI Bio Reports 6-Week Interim Biomarker R...
07/31/2025 13:03:35

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/22/2025 21:06:00

gri-bio-completes-enrollment-in-phase-2a-trial-of-gri-0621-for-idiopathic-pulmonary-fibrosis-2--and-6--week-interim-safety-results-demonstrated-gri-0621-to-be-safe-and-well-tolerated-in-the-first-12-and-24-patients-evaluated-respectively
GRI Bio Completes Enrollment In Phase 2a T...
07/01/2025 12:50:54

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited ...

gri-bio-reports-safety-results-at-interim-6-week-analysis-from-phase-2a-study-of-gri-0621-independent-data-monitoring-committee-recommended-to-continue-study-as-planned
GRI Bio Reports Safety Results At Interim ...
06/26/2025 12:05:03

hc-wainwright--co-reiterates-buy-on-gri-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on GRI ...
06/11/2025 11:08:56

HC Wainwright & Co. analyst Joseph Pantginis reiterates GRI Bio (NASDAQ:GRI) with a Buy and maintains $10 price target.

ascendiant-capital-maintains-buy-on-gri-bio-lowers-price-target-to-34
Ascendiant Capital Maintains Buy on GRI Bi...
05/27/2025 10:26:48

Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $40 to $34.

gri-bio-presents-preclinical-data-demonstrating-lead-program-gri-0621-has-anti-inflammatory-and-anti-fibrotic-effects-in-pulmonary-fibrosis-at-2025-ats-international-conference
GRI Bio Presents Preclinical Data Demonstr...
05/22/2025 12:03:53

Data presented at the 2025 American Thoracic Society (ATS) International ConferencePre-clinical and interim clinical results un...

gri-bio-q1-eps-580-misses-411-estimate
GRI Bio Q1 EPS $(5.80) Misses $(4.11) Esti...
05/15/2025 12:47:54

GRI Bio (NASDAQ:GRI) reported quarterly losses of $(5.80) per share which missed the analyst consensus estimate of $(4.11) by 4...

gri-bio-reports-interim-biomarker-results-from-phase-2a-study-evaluating-gri-0621-in-idiopathic-pulmonary-fibrosis-independent-data-monitoring-committee-recommended-study-continue-as-planned-as-no-safety-concerns-were-seen-in-the-data-reviewed
GRI Bio Reports Interim Biomarker Results ...
05/08/2025 12:46:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION